Context Therapeutics’ (CNTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $5.00 price target on the stock.

CNTX has been the topic of several other research reports. Piper Sandler started coverage on Context Therapeutics in a report on Thursday, May 16th. They set an overweight rating and a $4.50 target price on the stock. Piper Sandler Companies assumed coverage on Context Therapeutics in a report on Thursday, May 16th. They issued an overweight rating and a $4.50 price target on the stock. Finally, Maxim Group raised their price target on Context Therapeutics from $4.00 to $10.00 and gave the company a buy rating in a report on Thursday, May 9th.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $2.02 on Wednesday. The stock’s fifty day moving average is $1.93 and its 200-day moving average is $1.45. The stock has a market capitalization of $151.50 million, a PE ratio of -1.52 and a beta of 2.30. Context Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.24.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.15. As a group, analysts forecast that Context Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

An institutional investor recently bought a new position in Context Therapeutics stock. Opaleye Management Inc. purchased a new stake in Context Therapeutics Inc. (NASDAQ:CNTX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 975,000 shares of the company’s stock, valued at approximately $1,102,000. Opaleye Management Inc. owned about 6.11% of Context Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.